• Early scar tissue production is primarily controlled by tissue inflammation, wound hydration and temperature. Avogel^® is designed to reduce inflammation while increasing temperature and hydration;
  
  
• Mechanical tension is another major factor leading to scar growth. Several clinically accepted anti-hypertension drugs can be used to block the effect of tension on scar formation leading to reduced scar production. These drugs are the only drugs known to reactivate and soften older stable scars.
  

Avocet holds exclusive, worldwide licenses for the use of hydrogels in the treatment of scars, a position that provides near total control of any effective drug delivery system that can be designed for scar care. In June 2000, Avocet entered the US market with its first FDA-approved product, Avogel^®, a biocompatible hydrogel sheeting designed to reduce scars by topical application. Avocet has licensed several other patents that cover the use of novel and powerful drugs for scar control.

Avocet currently has two products on the market, Avogel and Avosil, which are currently used by patients around the country who desire to reduce the appearance of unwanted scars. Avocet is committed to bringing these effective and affordable products into a greater number of hospitals, pharmacies, and homes across the country. In order to expand the market for Avogel and Avosil, Avocet is seeking to partner with companies who would be interested in distributing and marketing our products to hospitals, pharmacies, burn care centers, and other healthcare centers. If you would like more information about partnering with Avocet, please feel free to contact out Business Development Team.

Avocet’s management staff and Board of Directors consist of experts in wound healing science, medicine and surgery, biopolymer technology, government regulation of medical products, and the cosmaceutical and medical products industries.

Inventor and Founder
Raphael C. Lee, MD, ScD, DSc, FACS
Professor of Surgery and Anatomy at University of Chicago Hospitals, Dr. Lee is the inventor of Avocet's core technology. He performed his residency at Harvard (Mass. General), interned at the University of Chicago and earned his MD at Temple University. In addition, Dr. Lee earned an electrical engineering doctorate (ScD) at MIT prior to joining the University of Chicago full-time in the 1980's. Dr. Lee has been researching novel uses of biocopatible polymers for cellular wound healing for the past 17 years and is currently the preeminent researcher in this field. He is the recipient of more than 25 scientific awards including a MacArthur Fellowship and the Searle Scholar Award. He is also the founder and innovator for Maroon Biotech, Inc., a company thad develops surfactant chaperones to restore structure and viability to cells disrupted by physical and chemical trauma.

Avocet is a privately financed company. For more information, please contact:

Avocet Polymer Technologies, Inc.
2225 West Harrison Street
Suite B
Chicago, IL 60612 USA
1-312-733-0669 (Toll-free: 1-866-352-SCAR)

Avocet Polymer Technologies is a class C corporation, and is incorporated in the State of Delaware.

_________________________________________________